Evolent Health(NYSE) EVH

Evolent Health, Inc. helps doctors manage care for complex illnesses. It works with health plans to lower specialty treatment costs. This company treats serious conditions like cancer and heart disease.

Solutions for Expensive Health Conditions

• Performance Suite: Manages specialty care where Evolent takes financial responsibility for patient costs; generated $484.5 million in revenue during the three months ended June 30, 2026.
• Specialty Technology and Services: Provides clinical tools and administrative support for specialty care providers; accounted for $78.2 million in revenue for the quarter ended June 30, 2026.
• Administrative Services: Supplies health plan management and claims processing infrastructure to partners; produced $48.0 million in revenue during the three-month period ended June 30, 2026.
• Surgery and Care Planning: Supports patients through specific surgical programs and advanced care decisions; contributed $41.9 million in revenue for the quarter ended June 30, 2026.

Big Changes and New Contracts

• Sold the Evolent Care Partners business in December 2025 to focus on its core technology and specialty care offerings.
• Started several new Performance Suite contracts during the first half of 2026 to drive revenue growth.
• Expanded oncology care services for an existing major customer during the six-month period ended June 30, 2026.
• Restructured capital by exchanging preferred stock for a new second lien loan facility in August 2025.

Connecting Care Through Technology

Evolent uses its proprietary technology platform, Identifi, to aggregate health data and recommend evidence-based clinical pathways for expensive treatments. By aligning financial incentives with these proven methods, the company helps health plans reduce medical waste while improving the patient experience.

A Look at Recent Results

• Total revenue rose to $652.5 million for the three-month period ended June 30, 2026, up 46.9% year over year.
• Net loss attributable to common shareholders was $55.0 million for the six-month period ended June 30, 2026.
• Medical Expense Ratio, which measures claims costs against revenue, reached 95.3% for the quarter ended June 30, 2026.
• Operating loss reached $9.6 million for the three months ended June 30, 2026, worsening by 717% year over year.
• Cash and cash equivalents totaled $115.7 million as of June 30, 2026.

Bottom Line

Evolent has evolved into a specialist in high-cost care management through risk-based contracts and clinical technology. Its strategy focuses on scaling proven clinical pathways while managing industry-wide increases in medical claims costs.